FBLG: FBLG: First patients dosed in Phase 1/2 trial of CYWC628 for diabetic foot ulcers

AI Summary

FibroBiologics (FBLG) announced the first patients have been enrolled and dosed in its randomized, multicenter Phase 1/2 trial of CYWC628 — a topically administered allogeneic fibroblast-spheroid therapy — for diabetic foot ulcers in Australia, with up to 120 patients randomized to standard of care (SoC) alone or SoC plus low or high dose CYWC628. The study will evaluate safety, tolerability and efficacy over up to 12 weeks with an interim analysis after six weeks; preclinical data suggest accelerated wound healing but no human efficacy data are reported yet.

Positives

First patients enrolled and dosed in Phase 1/2 trial (clinical milestone)
Randomized, multicenter design planned for up to 120 patients with SoC vs SoC+low/high dose and a 6-week interim analysis
CYWC628 is an allogeneic topical fibroblast-spheroid therapy with preclinical evidence of accelerated wound healing

Negatives

No clinical efficacy data yet — still early-stage (Phase 1/2)
Interim efficacy readout only after six weeks, so material results timeline is uncertain
Company disclosure flags typical development and liquidity risks